SLC5A2 and diabetes mellitus: This benefit of SGLT-2 inhibitors on COVID-19 mortality was not significantly affected by patient factors such as age, sex, hypertension, heart failure, HbA1c levels, metformin use, duration of diabetes, and BMI.